YSYoon Sunwoo

Yoon Sunwoo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoon Sunwoo has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expanding the Clinical Spectrum of Arboleda-Tham Syndrome

    by Jee Min Kim, Yoon Sunwoo, Haeryung Kim, Young Ho Kim, Jong Ho Cha, Seungbok Lee, Jung Min Ko, Byungchan Lim, Soo Yeon Kim, Jong-Hee Chae

    Background and ObjectivesArboleda-Tham syndrome (ARTHS) is a rare autosomal dominant neurodevelopmental disorder caused by pathogenic variants in the lysine acetyltransferase 6A (KAT6A) gene, chara...

  • Open Access

    Clinical usefulness of next-generation sequencing-based target gene sequencing in diagnosis of inherited bone marrow failure syndrome

    by Young Dai Kwon, Kyung Taek Hong, Juyeon Lee, Yoon Sunwoo, Yeseul Kim, Sung Im Cho, Hyun Jin Park, Bo Kyung Kim, Jee-Soo Lee, Jung Yoon Choi, et al.

    Inherited bone marrow failure syndromes are genetic hematologic disorders with increased cancer risk. Accurate diagnosis is crucial for appropriate management. This study assessed the clinical usefulness of next-generation sequencing (NGS)-based target gene sequencing in pediatric and AYA (adolescent and young adult) patients with hematologic abnormalities. From December 2019 to June 2023, 93 patients with suspected congenital hematologic diseases at a single institution underwent NGS-based testing. Medical records were retrospectively reviewed. The median age at diagnosis was 9.3 years (range 0.2–31.4), with 59.1% males. Indications for testing included specific medical histories (28 patients), persistent cytopenia or recurrent neutropenic fever (22 patients), changes in cytopenia patterns (11 patients), and other reasons (32 patients). Pathogenic variants were identified in 9/28 (32.1%), 3/22 (13.6%), 4/11 (36.4%), and 0/32 (0%). Overall, 16 patients (17.2%) had pathogenic variants, including FANCA, BRCA2, PMS2, ELANE, G6PC3 and VPS13B in patients with idiopathic neutropenia, and GATA2 in patients with suspected myelodysplastic syndrome. Genetic findings led to diagnostic revisions in 12 patients (12.9%), including reclassification of aplastic anemia (AA) as Fanconi anemia, Diamond-Blackfan anemia, or Shwachman-Diamond syndrome, prompting hematopoietic stem cell transplantation and altering cancer surveillance. Pathogenic variants were more frequently observed in patients with a specific medical history or changes in cytopenia, and in those with additional clinical features (cytogenetic abnormalities or non-severe AA). This study demonstrated the diagnostic usefulness of NGS-based target gene sequencing for pediatric and AYA patients with suspected genetic hematologic disorders, supporting the need for multicenter studies and standardized guideline development.


  • Open Access

    Variant of CHD1 gene resulting in a Korean case of Pilarowski-Bjornsson syndrome

    by Yoon Sunwoo, Soo Hyun Seo, Ho-Joong Kim, Moon Seok Park, Anna Cho

    Yoon Sunwoo, Soo Hyun Seo, Ho-Joong Kim, Moon Seok Park, and Anna Cho. J Genet Med 2022;19:111-4. https://doi.org/10.5734/JGM.2022.19.2.111